ArticleScientific reports2017
A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Semaglutide treatment in MOSH is associated with altered DNA methylation patterns of genes related to glycolipid metabolism.Scientific reports · 2026Article
- Messenger RNA delivery to islet β cells using conjugated lipid nanoparticles.Cell reports. Medicine · 2026Article
- Application of Machine Learning in Predicting Hepatic Metastasis or Primary Site in Gastroenteropancreatic Neuroendocrine Tumors.Current oncology (Toronto, Ont.) · 2023Article
- Targeted delivery of harmine to xenografted human pancreatic islets promotes robust cell proliferation.Scientific reports · 2022Article
- Single-Domain Antibody Theranostics on the Horizon.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells.Vaccines · 2022Article
- Imaging evaluation of the pancreas in diabetic patients.Abdominal radiology (New York) · 2022Review
- Multipotent Mesenchymal Stromal Cells Interact and Support Islet of Langerhans Viability and Function.Frontiers in endocrinology · 2022Review
- Potential of [Scientific reports · 2021Article
- The Current State of Beta-Cell-Mass PET Imaging for Diabetes Research and Therapies.Biomedicines · 2021Review
- Application of Single-Domain Antibodies ("Nanobodies") to Laboratory Diagnosis.Annals of laboratory medicine · 2021Review
- Radiolabeling Strategies of Nanobodies for Imaging Applications.Diagnostics (Basel, Switzerland) · 2021Review
- Nanobodies: new avenue to treat kidney disease.Cell and tissue research · 2021Review
- Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.Molecular diagnosis & therapy · 2021Review
- Nanobodies for Medical Imaging: About Ready for Prime Time?Biomolecules · 2021Review
- Nanobodies asRSC chemical biology · 2021Review
- Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor.Biomolecules · 2021Review
- Ways into Understanding HIF Inhibition.Cancers · 2021Review
- Nanobodies as Versatile Tool for Multiscale Imaging Modalities.Biomolecules · 2020Review
- Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor.Cellular immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are presently no reliable ways to quantify endocrine cell mass (ECM) in vivo, which prevents an accurate understanding of the progressive beta cell loss in diabetes or following islet transplantation. To address this unmet need, we coupled RNA sequencing of human pancreatic islets to a systems biology approach to identify new biomarkers of the endocrine pancreas. Dipeptidyl-Peptidase 6 (DPP6) was identified as a target whose mRNA expression is at least 25-fold higher in human pancreatic islets as compared to surrounding tissues and is not changed by proinflammatory cytokines. At the protein level, DPP6 localizes only in beta and alpha cells within the pancreas. We next generated a high-affinity camelid single-domain antibody (nanobody) targeting human DPP6. The nanobody was radiolabelled and in vivo SPECT/CT imaging and biodistribution studies were performed in immunodeficient mice that were either transplanted with DPP6-expressing Kelly neuroblastoma cells or insulin-producing human EndoC-βH1 cells. The human DPP6-expressing cells were clearly visualized in both models. In conclusion, we have identified a novel beta and alpha cell biomarker and developed a tracer for in vivo imaging of human insulin secreting cells. This provides a useful tool to non-invasively follow up intramuscularly implanted insulin secreting cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.